Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Electrophorus electricus | Acetylcholinesterase | References | |
Mus musculus | cholinergic receptor, muscarinic 1, CNS | Starlite/ChEMBL | References |
Rattus norvegicus | Muscarinic acetylcholine receptor M2 | Starlite/ChEMBL | References |
Homo sapiens | butyrylcholinesterase | Starlite/ChEMBL | References |
Equus caballus | Cholinesterase | References | |
Homo sapiens | acetylcholinesterase (Yt blood group) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | WLM domain containing protein, putative | 0.013 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0367 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0367 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0367 | 1 | 0.5 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.013 | 0 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0367 | 1 | 1 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0367 | 1 | 1 |
Onchocerca volvulus | 0.0367 | 1 | 1 | |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0367 | 1 | 1 |
Echinococcus granulosus | tumor protein p63 | 0.0355 | 0.951 | 0.951 |
Echinococcus granulosus | acetylcholinesterase | 0.0327 | 0.8343 | 0.8343 |
Leishmania major | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.013 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0367 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0327 | 0.8343 | 0.8343 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.013 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0367 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0367 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0367 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0367 | 1 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0367 | 1 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0367 | 1 | 1 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0367 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0327 | 0.8343 | 0.8343 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0367 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0327 | 0.8343 | 0.8343 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0367 | 1 | 1 |
Schistosoma mansoni | brg-1 associated factor | 0.0367 | 1 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.0355 | 0.951 | 0.951 |
Trypanosoma brucei | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0327 | 0.8343 | 0.8343 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.013 | 0 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.013 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0367 | 1 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0327 | 0.8343 | 0.8343 |
Leishmania major | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.013 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0327 | 0.8343 | 0.8343 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0367 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0327 | 0.8343 | 0.8343 |
Brugia malayi | Carboxylesterase family protein | 0.0327 | 0.8343 | 0.8343 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0327 | 0.8343 | 0.8343 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0367 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0327 | 0.8343 | 0.8343 |
Leishmania major | hypothetical protein, conserved | 0.013 | 0 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0327 | 0.8343 | 0.8343 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0367 | 1 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0367 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0367 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.013 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.013 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0327 | 0.8343 | 0.8343 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Approx. lethal dose (ADMET) | < 180 | Approximate lethal dose in mice. | ChEMBL. | 1507203 |
Approx. lethal dose (ADMET) | < 180 | Approximate lethal dose in mice. | ChEMBL. | 1507203 |
IC50 (binding) | = 0.47 uM | In vitro acetyl cholinesterase(AChE-I) inhibitory activity of the compound to determine its ability to reverse the cholinergic deficit characteristic of AD | ChEMBL. | 1507203 |
IC50 (binding) | = 0.47 uM | In vitro acetyl cholinesterase(AChE-I) inhibitory activity of the compound to determine its ability to reverse the cholinergic deficit characteristic of AD | ChEMBL. | 1507203 |
IC50 (binding) | = 0.47 uM | Inhibition of electric eel AChE using acetylthiocholine as substrate preincubated for 8 mins followed by substrate addition by Ellman's method | LITERATURE. | 27769620 |
IC50 (binding) | = 0.6 uM | Binding affinity of the compound against mouse Muscarinic acetylcholine receptor M2 using heart tissue and [3H]-N-methylscopolamine | ChEMBL. | 1507203 |
IC50 (binding) | = 0.6 uM | Binding affinity of the compound against mouse Muscarinic acetylcholine receptor M2 using heart tissue and [3H]-N-methylscopolamine | ChEMBL. | 1507203 |
IC50 (binding) | = 0.97 uM | Binding affinity of the compound against mouse Muscarinic acetylcholine receptor M1 using cerebral cortex and [3H]-pirenzepine | ChEMBL. | 1507203 |
IC50 (binding) | = 0.97 uM | Binding affinity of the compound against mouse Muscarinic acetylcholine receptor M1 using cerebral cortex and [3H]-pirenzepine | ChEMBL. | 1507203 |
IC50 (binding) | = 10 uM | In vitro Butyrylcholinesterase inhibitory activity of the compound to determine its ability to reverse the cholinergic deficit characteristic of AD | ChEMBL. | 1507203 |
IC50 (binding) | = 10 uM | In vitro Butyrylcholinesterase inhibitory activity of the compound to determine its ability to reverse the cholinergic deficit characteristic of AD | ChEMBL. | 1507203 |
IC50 (binding) | = 10 uM | Inhibition of equine serum BuChE using butyrylthiocholine as substrate preincubated for 8 mins followed by substrate addition by Ellman's method | LITERATURE. | 27769620 |
Ileal activity (functional) | < 0.1 uM | Concentration of the compound required to potentiate the contraction of isolated rat ileum produced by 1 x 10 e -7 M Ach by 20 % | ChEMBL. | 1507203 |
Inhibition (binding) | = 32 % | Displacement of [3H]QNB from muscarinic M3 receptor in rat brain homogenates at 1 uM after 60 mins relative to control | LITERATURE. | 27769620 |
Inhibition (binding) | = 74 % | Displacement of [3H]QNB from muscarinic M4 receptor in rat brain homogenates at 1 uM after 60 mins relative to control | LITERATURE. | 27769620 |
Inhibition (binding) | = 80 % | Displacement of [3H]QNB from muscarinic M1 receptor in rat brain homogenates at 1 uM after 60 mins relative to control | LITERATURE. | 27769620 |
Inhibition (binding) | = 97 % | Displacement of [3H]QNB from muscarinic M2 receptor in rat brain homogenates at 1 uM after 60 mins relative to control | LITERATURE. | 27769620 |
Ratio (binding) | = 0.06 | Ratio of IC50(M2 Receptor) to IC50(M1 Receptor) | ChEMBL. | 1507203 |
Ratio (binding) | = 22 | Ratio of IC50(BChE-I) to IC50(AChE-I) | ChEMBL. | 1507203 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.